MimiVax is a biotechnology company focused on developing innovative immunotherapies to improve outcomes and quality of life for patients suffering from devastating diseases, particularly cancer. The company operates in the biomedical sector and serves patients diagnosed with chronic and terminal illnesses, including glioblastoma, multiple myeloma, and neuroendocrine tumors. MimiVax's core product, SurVaxM, is an immunotherapy currently being studied in various clinical trials, showing promising results in increasing patient survival rates and reducing toxicity. The business model revolves around research and development, clinical trials, and collaborations with pharmaceutical companies like MERCK to bring their therapies to market. Revenue is generated through partnerships, grants, and donations, particularly from foundations like the Roswell Park Alliance Foundation, which supports early-phase clinical studies. MimiVax is committed to accelerating the pace of its clinical trials to deliver effective treatments to patients as quickly as possible.

Keywords: immunotherapy, cancer treatment, glioblastoma, SurVaxM, biomedical, clinical trials, survivin targeting, patient survival, biotechnology, Buffalo startup.